{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:45:02Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0956e-3408-77d0-9ff5-25b718c83293\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: olsalazine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 79.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0956e-3418-7243-b618-36f9387de779\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: olsalazine\nRegistry id: vr.tr.olsalazine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:53:48+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q347621", "registryId": "vr.tr.olsalazine", "name": "olsalazine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q347621/", "model": { "registry_id": "vr.tr.olsalazine", "name": "olsalazine", "purpose": "Enable an AI agent to recognise olsalazine, assess the identity and suitability of a material containing it, and determine which handling or use decisions require further evidence.", "definition": "Olsalazine is an azo-linked dimer of 5-aminosalicylic acid that acts as a prodrug, undergoing cleavage by colonic bacteria to release mesalazine for the treatment of ulcerative colitis.", "scope_statement": "This model owns the chemical identity, material state, quality, transformation behaviour and evidence-qualified use constraints of olsalazine under vr.tr.olsalazine in PHY / PHY.MAT, distinguishing the parent substance from its salts and finished medicines.", "in_scope": [ "Olsalazine molecular identity and form-specific identifiers", "Relationships between the parent acid, ionised forms and olsalazine sodium", "Sample composition, assay basis, impurities and material grade", "Physical properties, stability and storage conditions for the identified form", "Azo-bond cleavage and the relationship to mesalamine", "Substance handling hazards and links to applicable pharmaceutical restrictions" ], "out_of_scope": [ "Finished capsule formulations, excipients and packaging specifications", "Patient diagnosis, prescribing, dosing and treatment monitoring", "Ulcerative colitis as a disease model", "Complete manufacturing processes and production equipment", "Independent models of mesalamine, sulfasalazine or other related substances" ], "distinguishing_features": [ "Confirm the paired salicylic-acid ring structure joined through an azo linkage; mesalamine is the cleavage product rather than the intact parent. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f)", "Check counterions and protonation: olsalazine sodium is a disodium salt and must not inherit free-acid mass or composition assumptions. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f)", "Use structural evidence to distinguish olsalazine from similarly named salicylates and compounds with different substitution positions; name similarity alone is insufficient.", "Distinguish a chemically identified olsalazine material from a branded medicine by checking whether excipients, dosage strength and a product authorisation are part of the record." ], "characteristics": [ { "name": "Chemical identity", "kind": "category", "unit_or_values": "Structure-linked name and identifiers; free-acid formula C14H10N2O6 and CAS 15722-48-2 are reported by PubChem and require form matching. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Olsalazine)", "why_it_matters": "Prevents attaching information for a salt, metabolite or similarly named substance to the registry entry." }, { "name": "Salt and solvation state", "kind": "category", "unit_or_values": "Parent acid, specified salt or unresolved form; counterion stoichiometry and hydrate or solvate status", "why_it_matters": "Controls formula mass, assay interpretation and whether physical-property evidence transfers." }, { "name": "Olsalazine content", "kind": "measurement", "unit_or_values": "% w/w or mg/g; as-is, dried or anhydrous basis; expressed as identified salt or parent-acid equivalent", "why_it_matters": "Allows meaningful comparison between lots without confusing salt mass and active-moiety mass." }, { "name": "Related substances", "kind": "measurement", "unit_or_values": "Individual impurity and total impurity concentrations in % w/w or ppm, with method and reporting limits", "why_it_matters": "Separates intact olsalazine from cleavage products, synthesis residues and unidentified components." }, { "name": "Solid material state", "kind": "state", "unit_or_values": "Observed phase, crystalline or amorphous character, identified solid form, water content and test conditions", "why_it_matters": "Makes material-state changes visible before property or quality assumptions are reused." }, { "name": "Solubility", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with chemical form, solvent, pH, temperature and equilibration method", "why_it_matters": "Supports preparation and analysis without treating a condition-dependent value as universal." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "Transition or decomposition temperature in °C, with analytical method and heating conditions", "why_it_matters": "Distinguishes melting from decomposition and constrains processing conditions." }, { "name": "Azo-cleavage behaviour", "kind": "relation", "unit_or_values": "Olsalazine to mesalamine transformation; biological or experimental conditions, conversion extent and time", "why_it_matters": "Connects the intact substance to its prodrug function without assuming identical conversion in every environment." }, { "name": "Material disposition", "kind": "state", "unit_or_values": "Unassessed, quarantined, released for a specified use, expired or rejected; governing specification and evidence", "why_it_matters": "Prevents chemical identity alone from being treated as proof of pharmaceutical suitability." }, { "name": "Hazard and regulatory applicability", "kind": "category", "unit_or_values": "Form-specific SDS classification, jurisdiction, revision date, occupational limits if established, and linked medicinal authorisations", "why_it_matters": "Separates bulk-material precautions from restrictions applicable to particular medicinal products." } ], "affordances": [ "Match an olsalazine-labelled material to structure and form-specific identity evidence.", "Compare lots against an explicit olsalazine quality specification.", "Convert between salt mass and parent-acid equivalents when composition and assay basis are established.", "Select evidence-supported analytical, storage and handling conditions for the identified material.", "Trace conversion to mesalamine while preserving the distinction between parent substance and transformation products.", "Flag missing evidence that prevents release for a proposed research, manufacturing or pharmaceutical use." ], "agent_conduct": { "may": [ "Identify olsalazine and explain that it is a prodrug of mesalazine used for ulcerative colitis, citing sources.", "Report the grade, storage and expiry of a held stock." ], "must_not": [ "Recommend starting, stopping or dosing olsalazine for a person.", "Present it as interchangeable with other aminosalicylates without a prescriber's decision.", "Supply or suggest using expired or unlabelled material as medicine.", "Dismiss reported side effects such as diarrhoea without directing the person to their clinician." ], "requires_human": [ "Any treatment decision involving it.", "Disposing of stock of the active substance." ] }, "ethics": { "considerations": [ "People with inflammatory bowel disease depend on stable treatment, and wrong advice can cause flares.", "Patients' diagnoses are sensitive health data." ], "affected_parties": [ "Patients with ulcerative colitis", "Prescribers and pharmacists", "Laboratory staff" ] }, "owners": { "steward": "The pharmacy, manufacturer or laboratory holding it; the medicines regulator authorizes its use.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "A yellow crystalline powder as a substance; as a medicine, capsules labelled with the active substance.", "Identity is settled by the product label and laboratory analysis." ], "failure_modes_and_hazards": [ "Inappropriate use or stopping causes disease flares.", "Side effects missed or dismissed.", "Counterfeit products leave the disease untreated." ], "standards_and_regulation": [ "Globally Harmonized System of Classification and Labelling of Chemicals (GHS), United Nations." ], "what_it_is_for": [ "Olsalazine is encountered in prescription medicines used in the management of ulcerative colitis, including maintenance of remission.", "It is also encountered in pharmaceutical manufacturing, quality testing and research on medicines that release mesalazine in the colon." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q347621: olsalazine", "url": "https://www.wikidata.org/wiki/Q347621", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Olsalazine", "url": "https://en.wikipedia.org/wiki/Olsalazine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "olsalazine-identity-and-forms", "name": "Olsalazine identity and forms", "description": "Establish which chemical entity an olsalazine record or material actually denotes.", "rationale": "The registry name alone does not resolve parent acid, salt, ionisation state or product identity.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Recognise olsalazine through molecular connectivity and independently supported identifiers.", "findings": [ { "id": "azo-linked-parent-identity", "name": "Azo-linked parent identity", "description": "Identity assessment must establish the intact azo-linked structure and ring substitution pattern rather than rely on a salicylate name.", "questions": [ { "text": "Which reference structure establishes the azo linkage and substitution positions for vr.tr.olsalazine?", "kind": "definition", "id": "azo-linked-parent-identity-q01" }, { "text": "Which analytical evidence distinguishes this material from mesalamine, positional isomers and other azo-linked salicylates?", "kind": "measurement", "id": "azo-linked-parent-identity-q02" } ] } ] }, { "id": "parent-salt-and-product-boundaries", "name": "Parent, salt and product boundaries", "description": "Resolve which identifiers and properties belong to each chemical form.", "findings": [ { "id": "form-qualified-records", "name": "Form-qualified records", "description": "A parent-moiety relationship does not make acid, salt and capsule records interchangeable.", "questions": [ { "text": "Does the record describe the parent acid, a specified salt, an ionised species or a finished medicine?", "kind": "boundary", "id": "form-qualified-records-q01" }, { "text": "Which counterion, hydration and structural evidence supports each attached CAS, PubChem or EC identifier?", "kind": "provenance", "id": "form-qualified-records-q02" } ] } ] } ] }, { "id": "olsalazine-composition-and-quality", "name": "Olsalazine composition and quality", "description": "Determine how much olsalazine is present and whether the accompanying material permits the intended use.", "rationale": "Identity, purity and pharmaceutical suitability are separate judgements.", "layers": [ { "id": "assay-and-equivalence", "name": "Assay and equivalence", "description": "Make olsalazine content comparable across forms and reporting conventions.", "findings": [ { "id": "declared-assay-basis", "name": "Declared assay basis", "description": "An assay result needs an explicit chemical form, water basis and reference standard before it supports a mass-equivalence calculation.", "questions": [ { "text": "Is the assay expressed as olsalazine parent acid, olsalazine sodium or another explicitly defined basis?", "kind": "measurement", "id": "declared-assay-basis-q01" }, { "text": "Which reference standard and corrections for water, solvent or counterions support the reported content?", "kind": "provenance", "id": "declared-assay-basis-q02" } ] } ] }, { "id": "impurities-and-release", "name": "Impurities and release", "description": "Assess related substances and lot suitability against an identified specification.", "findings": [ { "id": "intact-parent-and-related-substances", "name": "Intact parent and related substances", "description": "The quality assessment should distinguish olsalazine from free mesalamine and other detected components without presuming their origin.", "questions": [ { "text": "What concentrations of mesalamine, other identified impurities and unresolved chromatographic peaks are measured?", "kind": "measurement", "id": "intact-parent-and-related-substances-q01" }, { "text": "Which use-specific specification determines whether this lot can be released, reanalysed or rejected?", "kind": "action", "id": "intact-parent-and-related-substances-q02" } ] } ] } ] }, { "id": "olsalazine-physical-state-and-stability", "name": "Olsalazine physical state and stability", "description": "Qualify physical properties and storage behaviour by chemical form and conditions.", "rationale": "Unqualified constants can mislead preparation, analysis and storage decisions.", "layers": [ { "id": "solid-and-solution-behaviour", "name": "Solid and solution behaviour", "description": "Characterise the actual solid and its behaviour in specified media.", "findings": [ { "id": "condition-specific-properties", "name": "Condition-specific properties", "description": "Solubility and thermal measurements should remain attached to the tested olsalazine form and method.", "questions": [ { "text": "What solubility is measured for this form at the stated pH, solvent composition and temperature?", "kind": "measurement", "id": "condition-specific-properties-q01" }, { "text": "Does thermal analysis show melting, decomposition or another transition, and under what test conditions?", "kind": "measurement", "id": "condition-specific-properties-q02" } ] } ] }, { "id": "storage-and-change-detection", "name": "Storage and change detection", "description": "Connect storage history to demonstrated retention of olsalazine quality.", "findings": [ { "id": "stability-supported-disposition", "name": "Stability-supported disposition", "description": "Storage limits and retest periods require evidence for the material form and container concerned.", "questions": [ { "text": "Which studies establish acceptable exposure to temperature, humidity and light for this material?", "kind": "provenance", "id": "stability-supported-disposition-q01" }, { "text": "Which excursion or analytical change requires quarantine or repeat testing before further use?", "kind": "action", "id": "stability-supported-disposition-q02" } ] } ] } ] }, { "id": "olsalazine-bioconversion", "name": "Olsalazine bioconversion", "description": "Represent the parent substance's conversion to mesalamine and the limits of that evidence.", "rationale": "The azo-linked parent and released mesalamine have distinct identities and roles.", "layers": [ { "id": "azo-cleavage-and-products", "name": "Azo cleavage and products", "description": "Describe the transformation responsible for olsalazine's prodrug role.", "findings": [ { "id": "colonic-mesalamine-release", "name": "Colonic mesalamine release", "description": "Colonic bacteria cleave olsalazine's azo bond to release two molecules of mesalamine; this relationship does not establish conversion completeness in an arbitrary sample. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f)", "questions": [ { "text": "Which biological or experimental conditions support cleavage of this olsalazine material to mesalamine?", "kind": "definition", "id": "colonic-mesalamine-release-q01" }, { "text": "What conversion extent, product identity and mass balance were measured over what interval?", "kind": "measurement", "id": "colonic-mesalamine-release-q02" } ] } ] }, { "id": "biological-role-boundaries", "name": "Biological role boundaries", "description": "Keep transformation evidence distinct from clinical effectiveness claims.", "findings": [ { "id": "prodrug-evidence-transfer", "name": "Prodrug evidence transfer", "description": "A demonstrated chemical conversion does not independently establish clinical equivalence between olsalazine materials or medicines.", "questions": [ { "text": "Does the evidence concern bulk olsalazine, a particular formulation, an experimental system or treated patients?", "kind": "boundary", "id": "prodrug-evidence-transfer-q01" }, { "text": "Which evidence is needed before a conversion result can support the proposed pharmaceutical use?", "kind": "action", "id": "prodrug-evidence-transfer-q02" } ] } ] } ] }, { "id": "olsalazine-handling-and-use-constraints", "name": "Olsalazine handling and use constraints", "description": "Connect material hazards and pharmaceutical context to justified actions.", "rationale": "Bulk-substance handling evidence and medicinal-product labelling answer different operational questions.", "layers": [ { "id": "bulk-material-hazards", "name": "Bulk material hazards", "description": "Establish applicable precautions for the actual olsalazine material.", "findings": [ { "id": "form-specific-hazard-evidence", "name": "Form-specific hazard evidence", "description": "Hazard classification and exposure controls must be supported by an applicable SDS or authoritative assessment.", "questions": [ { "text": "Which current SDS covers this chemical form, concentration and supplier material, and what classification does it state?", "kind": "provenance", "id": "form-specific-hazard-evidence-q01" }, { "text": "What containment, protective equipment and waste route follow from that evidence for the intended handling operation?", "kind": "action", "id": "form-specific-hazard-evidence-q02" } ] } ] }, { "id": "pharmaceutical-context", "name": "Pharmaceutical context", "description": "Link olsalazine to medicinal evidence without importing product-specific instructions into the substance identity.", "findings": [ { "id": "authorisation-and-safety-links", "name": "Authorisation and safety links", "description": "The cited US olsalazine sodium label covers maintenance of ulcerative-colitis remission in adults intolerant of sulfasalazine and includes renal and hypersensitivity precautions. These are product-context links. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f)", "questions": [ { "text": "Which jurisdiction, authorised product and label revision support the proposed medicinal-use claim?", "kind": "provenance", "id": "authorisation-and-safety-links-q01" }, { "text": "Which decisions require the linked product and patient models, including contraindication assessment and monitoring?", "kind": "boundary", "id": "authorisation-and-safety-links-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recall-based information; no sources were consulted.", "Verify CAS, PubChem and EC identifiers separately for the free acid and disodium salt, including any hydration state.", "Check current jurisdiction-specific labeling for indications and safety details; physical constants, purity specifications and GHS classifications are not established here." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of olsalazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Olsalazine free acid", "Olsalazine disodium salt" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of olsalazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (WHO)", "value_or_pattern": "olsalazine", "note": "Distinguish the parent compound from its disodium salt in substance records." }, { "scheme": "WHO Anatomical Therapeutic Chemical classification", "value_or_pattern": "A07EC03", "note": "Classified among aminosalicylic acid and similar agents." }, { "scheme": "Molecular formula", "value_or_pattern": "C14H10N2O6", "note": "Formula of the free acid; the anhydrous disodium salt is C14H8N2Na2O6." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of olsalazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Oral administration as olsalazine sodium to maintain remission in ulcerative colitis." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of olsalazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of free acid", "typical_range": "302.24", "unit": "g/mol" }, { "quantity": "Molar mass of anhydrous disodium salt", "typical_range": "346.20", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of olsalazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Diarrhea can limit tolerability.", "Abdominal pain and nausea can occur.", "Hypersensitivity or acute intolerance can resemble worsening inflammatory bowel disease.", "Renal injury, including interstitial nephritis, is a recognized concern with aminosalicylate therapy.", "Pancreatitis is a reported adverse reaction." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of olsalazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, product availability, brand names and prescribing information vary by jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of olsalazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Mesalazine (mesalamine)", "difference": "Mesalazine is 5-aminosalicylic acid itself; olsalazine must undergo azo-bond cleavage to release two mesalazine molecules." }, { "name": "Sulfasalazine", "difference": "Sulfasalazine links 5-aminosalicylic acid to sulfapyridine, whereas olsalazine links two 5-aminosalicylic acid units." }, { "name": "Balsalazide", "difference": "Balsalazide links one 5-aminosalicylic acid unit to a different carrier rather than to a second identical unit." }, { "name": "Olsalazine sodium medicinal product", "difference": "A medicinal product includes a specified salt, dose, formulation and excipients; the registered substance is its chemical constituent." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of olsalazine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does the authoritative registry intend olsalazine to denote only the parent acid or the active moiety across salts, and does an existing world model already cover that scope?", "Which structure-specific PubChem CID and EC identifiers resolve the parent acid and sodium salt without conflating alternative structure records?", "Which authoritative specification establishes olsalazine assay methods, impurity identities, acceptance limits and pharmaceutical-grade requirements?", "What measured solubility, solid-form, thermal-decomposition and storage-stability data are available for each relevant chemical form?", "Which current form-specific GHS classifications, occupational exposure limits if any, and environmental disposal requirements apply in the intended jurisdiction?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }